Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline must be read in its entirety to determine coverage eligibility, if any. This Medical Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines.
Hematopoietic Stem Cell Transplantation (SCT):
Hematopoietic stem cells form blood and immune cells. SCT is a procedure in which hematopoietic stem cells are infused into a recipient with deficient bone marrow function. Bone marrow stem cells may be obtained from the transplant recipient (autologous SCT) or a donor (allogeneic SCT). They can be harvested from bone marrow, peripheral blood, or umbilical cord blood and placenta shortly after a delivery. SCT may also be referred to as bone marrow transplant (BMT).
High-Dose Chemotherapy (HDC):
HDC is the administration of myelotoxic agents at doses sufficient to cause bone marrow failure. Myeloablative chemotherapy eradicates cancerous cells from the blood and bone marrow and inhibits the immune response against the donor bone marrow. HDC may be given with or without total body radiation.
Nonmyeloablative Chemotherapy With Allogeneic Stem Cell Transplantation (SCT):
Nonmyeloablative or reduced-intensity conditioning (RIC) is the administration of a lower dose of chemotherapy that is sufficient to eradicate the hematopoietic cells but does not completely destroy the bone marrow. RIC regimens attempt to reduce adverse effects secondary to bone marrow toxicity and allow for relatively prompt hematopoietic recovery. Nonmyeloablative chemotherapy may also be referred to as RIC, "mini transplant" or "transplant lite". Donor Types:
From a third-party donor ▪ Autologous:
From an individual's own bone marrow and/or circulating blood 
STEM CELL TRANSPLANTATION FOR NON-HODGKIN LYMPHOMAS (cont.)

Definitions:
Refractory/Primary Refractory: The disease is resistant to treatment and does not achieve a complete remission.
Relapse:
The recurrence of a disease or symptoms after apparent recovery.
Remission:
Period of time when cancer is responding to treatment or is under control. In complete remission, all signs and symptoms of the disease have disappeared.
Tandem Transplant: Two successive cycles of high-dose chemotherapy, each followed by infusion of autologous stem cells, whether or not there is evidence of persistent disease following the first treatment.
Criteria:
All stem cell transplants will be reviewed by the medical director(s) and/or clinical advisor(s).
Pretransplantation Evaluation:
Human Leukocyte Antigen (HLA) typing and Matched Unrelated Donor (MUD) searches may be approved by the coordinator if medical necessity criteria are met. HLA typing may use serologic tissue and/or DNA (gene) for more precise matching.
The psychosocial criteria listed below must only be met prior to the actual transplant procedure.
 Pretransplantation evaluation with documentation of ALL of the following:
1. Psychosocial screen with documentation of ALL of the following:
▪ Drug/alcohol screen with documentation of ONE of the following:
-No drug/alcohol abuse by history -Drug and alcohol free for a period greater than or equal to 6 months ▪ Behavioral health disorder screening with documentation of ONE of the following: Performance status tables are located at the end of the Criteria section.
Pretransplantation Neurological Evaluation:
 Neurological screen with documentation of ONE of the following:  HDC with autologous SCT or HDC with allogeneic SCT using a myeloablative conditioning regimen for an individual with follicular lymphoma is considered medically necessary with documentation of ALL of the following:
1. Pretransplantation evaluation criteria above 2. ANY of the following:
▪ As salvage therapy for individuals who do not achieve complete remission after first-line treatment (induction) with a full course of standard-dose chemotherapy ▪ To achieve or consolidate complete remission for those in a first or subsequent chemosensitive relapse, whether or not their lymphoma has undergone transformation to a higher grade. 
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STEM CELL TRANSPLANTATION FOR NON-HODGKIN LYMPHOMAS (cont.)
Criteria: (cont.) Follicular Lymphoma: (cont.)
 If above criteria not met, HDC with autologous SCT or HDC with allogeneic SCT using a myeloablative conditioning regimen for an individual with follicular lymphoma is considered experimental or investigational 2 based upon:
1. Insufficient scientific evidence to permit conclusions concerning the effect on health outcomes, and 2. Insufficient evidence to support improvement of the net health outcome, and 3. Insufficient evidence to support improvement of the net health outcome as much as, or more than, established alternatives.
 Nonmyeloablative reduced-intensity conditioning (RIC) with allogeneic SCT for NHL (all subtypes) for an individual who meets criteria for allogeneic SCT but is medically unable to tolerate HDC is considered medically necessary.
 Tandem HDC with autologous and/or allogeneic SCT for an individual with follicular lymphoma is considered experimental or investigational 2 based upon:
Mantle Cell Lymphoma:
 HDC with allogeneic SCT for an individual with mantle cell lymphoma is considered medically necessary with documentation of ALL of the following:
1. Pretransplantation evaluation and pretransplantation neurological evaluation criteria above 2. ANY of the following:  HDC with autologous SCT for an individual with mantle cell lymphoma is considered medically necessary with documentation of ALL of the following:
1. Pretransplantation evaluation and pretransplantation neurological evaluation criteria above 2. ANY of the following:
▪ 1st complete remission but at high risk of relapse ▪ 1st complete remission not achieved ▪ Relapsed lymphoma ▪ Relapse with transformation  Nonmyeloablative reduced-intensity conditioning (RIC) with allogeneic SCT for NHL (all subtypes) for an individual who meets criteria for allogeneic SCT but is medically unable to tolerate HDC is considered medically necessary.
 SCT for treatment of an individual with mantle cell lymphoma for all indications not previously listed or if above criteria not met is considered experimental or investigational 2 based upon:
These treatments include, but are not limited to:
▪ HDC with autologous SCT for mantle cell lymphoma salvage therapy ▪ HDC with allogeneic or autologous SCT for initial therapy ▪ HDC with allogeneic SCT for mantle cell relapse after a prior course of HDC with autologous SCT if autologous SCT was less than 6 months ago ▪ Tandem HDC with autologous and/or allogeneic SCT 
STEM CELL TRANSPLANTATION FOR NON-HODGKIN LYMPHOMAS (cont.)
Criteria: (cont.)
Peripheral T-Cell Lymphoma (including NK-Cell Neoplasms and T-Cell Neoplasms):
 HDC with autologous SCT for an individual with peripheral T-cell lymphoma is considered medically necessary with documentation of ALL of the following:
1. Pretransplantation evaluation criteria and neurological evaluation criteria above 2. ANY of the following:
▪ 1st complete remission but at high risk of relapse ▪ 1st complete remission not achieved ▪ Salvage therapy  HDC with allogeneic SCT for salvage therapy for an individual with peripheral T-cell lymphoma is considered medically necessary with documentation of pretransplantation evaluation criteria and neurological evaluation criteria above.
 Nonmyeloablative reduced-intensity conditioning (RIC) with allogeneic SCT for NHL (all subtypes) for individual who meets criteria for allogeneic SCT but is medically unable to tolerate HDC is considered medically necessary.
 SCT for treatment of an individual with peripheral T-cell lymphoma for all other indications not previously listed or if above criteria not met is considered experimental or investigational 2 based upon:
These treatments include, but are not limited to:
▪ HDC with allogeneic SCT to consolidate a first remission ▪ Tandem HDC with autologous and/or allogeneic SCT  Nonmyeloablative reduced-intensity conditioning (RIC) with allogeneic SCT for NHL (all subtypes) for individual who meets criteria for allogeneic SCT but is medically unable to tolerate HDC is considered medically necessary.
 The following treatments for an individual with other indolent subtypes are considered experimental or investigational 2 based upon:
These treatments include:
▪ HDC with allogeneic or autologous SCT for initial therapy ▪ HDC with allogeneic SCT for relapse after a prior course of HDC with autologous SCT if autologous SCT was less than 6 months ago ▪ Tandem HDC with autologous and/or allogeneic SCT for any subtype 2 Although specific transplantation procedures may be considered experimental or investigational and therefore not eligible for coverage under standard medical benefits, these procedures may be eligible for coverage based upon Arizona Revised Statutes §20-2326 concerning Cancer Clinical Trials. Other subtypes include Anaplastic Large Cell Lymphoma, Burkitt's Lymphoma and Diffuse Large B Cell Lymphoma. 
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